All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your ALL Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2023-01-06T09:16:29.000Z

How can you increase asparaginase adherence and manage hypersensitivity in adults with ALL?

Jan 6, 2023
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in ALL.

Bookmark this article

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the ALL Hub spoke with Kjeld Schmiegelow, University of Copenhagen, Copenhagen, DK. We asked, How can you increase asparaginase adherence and manage hypersensitivity in younger and older adults with ALL?

How can you increase asparaginase adherence & manage hypersensitivity in adults with ALL?

Schmiegelow begins by discussing the main challenges associated with asparaginase treatment, such as recognizing when it should be incorporated into therapy and the management severe toxicities; he highlights several studies examining the response to treatment in terms of effectiveness and the likelihood of relapse. He then goes on to mention the burden of toxicities including hypersensitivity, thromboembolism, hyperlipidemia, and pancreatitis. He concludes with hypersensitivity management strategies, explaining that re-exposure can be useful in patients with an anticipated high risk of relapse whereas truncation of asparaginase can be helpful in low-risk (MRD negative postinduction) patients.

Newsletter

Subscribe to get the best content related to ALL delivered to your inbox